Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Rang in Aktien #27034
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Aktienkurs
$1.48
Zuletzt synchronisiert: 2023-05-31
Marktkapitalisierung
$35.54M
Veränderung (1 Tag)
-5.73%
Veränderung (1 Jahr)
0.00%
Land
US
Handel TCR2 Therapeutics Inc. (TCRR)

Kategorie

Aktien-Split-Historie für TCR2 Therapeutics Inc. (TCRR)
Die Aktie TCR2 Therapeutics Inc. (Symbol: TCRR) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 20, 2026 statt.
Eine TCRR-Aktie, die vor dem Aug 20, 2026 gekauft wurde, entspricht heute 0 TCRR-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH